SCHEMBL7937099

SCHEMBL7937099

COc1ccccc1C(/C=C/c1ccccc1)([C@H](C(=O)NOC1CCCCO1)[C@@H](CC(C)C)C(=O)NN)S(C)(=O)=O

nearest known ligand 0.33

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
P2RX3 P56373 1/20 0.32
TP53 P04637 1/20 0.32
THRB P10828 1/20 0.32
CTSK P43235 2/20 0.31
CYP1A2 P05177 1/20 0.31
CYP3A4 P08684 1/20 0.31
CYP2C9 P11712 1/20 0.31
CYP2C19 P33261 1/20 0.31
RECQL P46063 1/20 0.31
ITGB1 P05556 1/20 0.31
ITGA4 P13612 1/20 0.31
MMP2 P08253 2/20 0.31
MMP9 P14780 2/20 0.31
ANPEP P15144 2/20 0.31
LTA4H P09960 1/20 0.31
LAP3 P28838 1/20 0.31
NPEPPS P55786 1/20 0.31
ERAP2 Q6P179 1/20 0.31
ERAP1 Q9NZ08 1/20 0.31
ADAM17 P78536 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6940018 0.89 MMP2 (0.33) P2RX3CTSKMMP2MMP9ANPEP
SCHEMBL6943194 0.88 P2RX3 (0.30) P2RX3
SCHEMBL6945957 0.86 ADAM17 (0.34) P2RX3MMP2MMP9ANPEPLTA4H
SCHEMBL6943373 0.85 ADAM17 (0.33) P2RX3CTSKMMP2MMP9ANPEP
SCHEMBL6937784 0.85 ADAM17 (0.33) P2RX3CTSKMMP2MMP9ANPEP
SCHEMBL6943556 0.84 ADAM17 (0.33) P2RX3MMP2MMP9ANPEPLTA4H
SCHEMBL8111706 0.84 ADAM17 (0.33) P2RX3MMP2MMP9ANPEPLTA4H
SCHEMBL6942209 0.84 ADAM17 (0.33) P2RX3MMP2MMP9ANPEPLTA4H
SCHEMBL6940960 0.83 TP53 (0.31) TP53KDM4EMEN1ALDH1A1KMT2A
SCHEMBL6945554 0.83 ADAM17 (0.33) P2RX3MMP2MMP9ANPEPLTA4H

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6235787-B1 ANTIINFLAMMATORY AGENTS; RHEUMATIC DISEASES; BONE DISORDERS; SKIN DISORDERS; MULTIPLE SCLEROSIS HOFFMANN-LA ROCHE INC. 2001-05-22 US disclosed